February 27, 2023: Adamis Pharmaceuticals announces merger with DMK Pharmaceuticals. Read the press release. Watch the video.
Adamis Pharmaceuticals logo - Click here to go back to the homepage
  • About
    • Overview
    • Management
    • Board of Directors
  • Products
    • SYMJEPI® (epinephrine)
    • ZIMHI® (naloxone)
  • Pipeline
    • Specialty Pharmaceuticals
    • APC-400 (tempol) – Capsule
  • Patients
  • Investors & Media
  • Careers
    • Careers
    • Partnerships
  • Contact Us
Menu
  • About
    • Overview
    • Management
    • Board of Directors
  • Products
    • SYMJEPI® (epinephrine)
    • ZIMHI® (naloxone)
  • Pipeline
    • Specialty Pharmaceuticals
    • APC-400 (tempol) – Capsule
  • Patients
  • Investors & Media
  • Careers
    • Careers
    • Partnerships
  • Contact Us

Category: SYMJEPI Press

CBC News (7/9/19): Novartis launches rival to EpiPen for allergy emergencies in U.S.

Contemporary Clinic (7/9/19): New Epinephrine Injection Launched in Retail Pharmacies

Pharma Letter (7/9/19): Sandoz debuts US retail sales of Symjepi

Pharmacy Times (7/9/19): Launch of New Epinephrine Injection Extended to Include Retail Pharmacies

Seeking Alpha (7/9/19): Sandoz extends SYMJEPI injection launch to US pharmacies

Fox Business (7/9/19): Novartis to sell allergy shots in the U.S. amid EpiPen shortage

Reuters (7/9/19): Novartis to sell epinephrine injector in U.S. Pharmacies amid EpiPen shortage

Becker’s Hospital Review (7/9/19): Generic alternative to EpiPen released amid allergy treatment shortage

FirstWord Pharma (7/9/19): Novartis extends SYMJEPI launch to US pharmacies amid shortage of Mylan’s EpiPen

← older

Sign Up For Adamis Email Alerts

Choose Your Preferences
Adamis Pharmaceuticals logo - Click here to go back to the homepage

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease.

Linkedin Twitter

COMPANY

  • About Us
  • Overview
  • Leadership
  • Board of Directors

PRODUCTS

  • SYMJEPI® (epinephrine)
  • ZIMHI® (naloxone)

PIPELINE

  • Specialty Pharmaceuticals
  • APC-400 (tempol) – Capsule

INVESTORS & MEDIA

  • Overview
  • News & Releases
  • Stock Information
  • SEC Filings
  • Events and Presentations
  • Corporate Governance
  • Email Alerts

CONNECT

  • Careers
  • Partnerships
  • Contact Us

© 2023 Copyright Adamis Pharmaceuticals Corporation

  • Terms and Conditions
  • Privacy Policy
  • Accessibility Statement